Literature DB >> 3553034

Eosinophil response in mast cell-deficient W/WV mice.

Y Nawa, M Owhashi, J Imai, T Abe.   

Abstract

The combination of cyclophosphamide treatment and Toxocara canis infection is known as an effective way of causing a high level of eosinophilia in mice. When this treatment was applied to congenitally anemic, mast cell-deficient W/WV mice, eosinophil response was far less than that of their normal littermate +/+ mice. The degree of the defective eosinophil response in the peripheral blood of W/WV mice was severer than that in the bone marrow. The defective eosinophil response of W/WV mice was completely restored by bone marrow grafting 8 weeks prior to cyclophosphamide treatment and T. canis infection. The kinetics of the recovery of eosinophil response in the bone marrow of W/WV mice after bone marrow grafting was faster than that in the peripheral blood. Chemotactic reactivity of eosinophils obtained from bone marrow or peritoneal cavity of W/WV mice was essentially comparable to that of +/+ mice. These results suggest that, in addition to the production of eosinophils in the bone marrow, mast cell-derived factors play an important role in the mediation of peripheral blood eosinophilia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3553034     DOI: 10.1159/000234323

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  3 in total

1.  Role of mast cells in ion transport abnormalities associated with intestinal anaphylaxis. Correction of the diminished secretory response in genetically mast cell-deficient W/Wv mice by bone marrow transplantation.

Authors:  M H Perdue; S Masson; B K Wershil; S J Galli
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

Review 2.  Eosinophils: a review.

Authors:  B J McEwen
Journal:  Vet Res Commun       Date:  1992       Impact factor: 2.459

3.  Mast cells are not essential to inflammation in murine model of colitis.

Authors:  K W Chin; K E Barrett
Journal:  Dig Dis Sci       Date:  1994-03       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.